Equity Long-Short Analyst

Pyari Menon

Equity Bottom-Up

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)'s</a></strong> Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. </li>
<li>Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.</li>
<li>Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.</li>
</ul>



CVRx (CVRX US)'s Barostim, is the only neuromodulation device designed to treat heart failure and resistant hypertension. We see CVRX as a buyout target. 
Growth will be driven by growing elderly population, and rising rates of diabetes and hypertension putting more people in cardiac decline.
Trials suggest that Barostim is a cost-effective treatment, quality of life improving therapy when compared with traditional optimal medical management in patients with resistant hypertension.


CVRx: Enhancing Cardiac Care Through Neuromodulation

United States

CVRx, Inc. develops and manufactures medical devices. The Company specializes in technology for an implantable device for the treatment of hypertension and heart failure that triggers the body's master blood flow regulation system. CVRx serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CVRx: Enhancing Cardiac Care Through Neuromodulation

One of a kind innovative Barostim technology, strong clinical results, and robust growth potential in cardiovascular care.

Pyari Menon